Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Valbiotis S.A.S. is a French biotechnology company that specializes in innovative medical solutions designed to prevent and address major worldwide health challenges. At the heart of Valbiotis' mission is its dedication to developing plant-based solutions that demonstrate clinical effectiveness in the prevention of metabolic diseases such as Type 2 diabetes, cardiovascular disease, and other linked pathologies. By utilizing proprietary technology and collaborating with leading scientific institutions, Valbiotis develops products aimed at reducing the risk of these diseases before they become critical health problems. The company operates within the pharmaceutical and wellness sectors, with a focus on non-prescription markets that could alleviate the burden on healthcare systems globally. Significant in the health industry, Valbiotis plays a crucial role in pioneering preventative healthcare trends, fostering healthier lifestyles through science-backed phytotherapy. Since its inception, Valbiotis has built a strong portfolio of interim products that link plant-based active ingredients with rigorous clinical validation, influencing the landscape of preventative health solutions.
The business is unprofitable at the operating level (-1049.17% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 417.1% YoY with margins expanding 4907.4pp.
ROIC dropped from -38.69% to -53.32%, capital efficiency is deteriorating. Negative free cash flow of -€8M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
€905K
▲ +417.1% YoY
Net Income (TTM)
-€9M
▲ +6.1% YoY
Op. Margin
-1049.17%
▲ +4907.4pp YoY
ROIC
-53.32%
▼ -14.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€8M
▲ +30.6% YoY
Op. Cash Flow (TTM)
-€8M
▲ +9.6% YoY
Net Debt
-€4M
Net Cash Position
Cash & Equiv.
€9M
3Y CAGR: +4.9%
Continue Research